<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03652337</url>
  </required_header>
  <id_info>
    <org_study_id>18-04-003</org_study_id>
    <nct_id>NCT03652337</nct_id>
  </id_info>
  <brief_title>Meibomian Gland Dysfunction Management</brief_title>
  <official_title>Meibomian Gland Dysfunction Management to Relieve Contact Lens Discomfort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of the Incarnate Word</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Academy of Optometry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of the Incarnate Word</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare electronic debridement of the eyelid margin (BlephEx)
      to manual debridement of the eyelid margin as treatment options for patients intolerant to
      contact lens wear consequent to Meibomian gland dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 10, 2018</start_date>
  <completion_date type="Anticipated">April 10, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic relief</measure>
    <time_frame>60 days</time_frame>
    <description>Betterment of symptoms (improvement in contact lens discomfort) will be measured using two different surveys - Ocular Surface Disease Index (OSID) and Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8). The OSDI scores can range from 0 to 100. The CLDEQ-8 scores can range from 0 to 37. In both the questionnaires, a lowering of the score during follow-up visits represents a betterment of symptoms suffered by the patient. The numerical change in the scores on these two questionnaires will be documented as the change in symptom profile of the patient (betterment / worsening / stability).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Meibography</measure>
    <time_frame>60 days</time_frame>
    <description>Meibomian gland imaging will be performed to document any changes in the Meibomian gland during the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lissamine green staining grade of the lid margin</measure>
    <time_frame>60 days</time_frame>
    <description>The lid margin will be stained with Lissamine green dye. For the purpose of this study, Lissamine green staining of the eyelid margins will be graded from 0 to 4. (Zero representing &quot;normal&quot; or &quot;no&quot; staining; Four representing the highest degree of staining). During the course of the study, a decrease in lid margin staining will indicate a betterment of the health of the eyelid margin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory activity</measure>
    <time_frame>60 days</time_frame>
    <description>The presence or absence of Matrix Metalloproteinase-9 (MMP-9) in the tear fluid will be documented during the study visits. Presence of MMP-9 in the tear fluid indicates the presence of inflammatory activity in the tear fluid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear break-up time</measure>
    <time_frame>60 days</time_frame>
    <description>Improvement in non-invasive tear break-up time measurement will be an objective outcome of the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Contact Lens Discomfort</condition>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>BlephEx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects who are enrolled in this arm will undergo electronic lid margin debridement using the BlephEx instrument.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Manual debridement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects who are enrolled in this arm will undergo manual lid margin debridement using a stainless steel ophthalmic golf spud.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BlephEx</intervention_name>
    <description>Electronic lid margin debridement</description>
    <arm_group_label>BlephEx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Manual debridement</intervention_name>
    <description>Manual lid margin debridement</description>
    <arm_group_label>Manual debridement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Habitual contact lens wearers whose contact lens wear time has reduced due to MGD will
             be preferentially considered for this study. Subjects who currently cannot wear
             contact lenses due to MGD may be considered on a case-by-case basis.

        Exclusion Criteria:

          -  Subjects who are currently using any prescription ophthalmic medications (such as
             antibiotics, steroids and immunomodulatory drugs) will be excluded from participation.

          -  Subjects who have active ocular infections will be excluded from participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srihari Narayanan, OD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rosenberg School of Optometry</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Korb DR, Blackie CA. Debridement-scaling: a new procedure that increases Meibomian gland function and reduces dry eye symptoms. Cornea. 2013 Dec;32(12):1554-7. doi: 10.1097/ICO.0b013e3182a73843.</citation>
    <PMID>24145633</PMID>
  </results_reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>September 4, 2018</last_update_submitted>
  <last_update_submitted_qc>September 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD.</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>March 30, 2020</submitted>
    <returned>April 10, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

